Targeting the TRIM28–EZH2 Protein–Protein Interface With Cysteine‐Reactive Covalent Inhibitors: A Computational Blueprint for Cancer Therapy
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.202502892 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Ibrahim Oluwatobi Kehinde und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Bio-Computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: Cysteine, Enhancer of Zeste Homolog 2 Protein, Tripartite Motif-Containing Protein 28, Small Molecule Libraries. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aberrant protein–protein interactions (PPIs) play crucial roles in cancer progression by driving transcriptional repression and epigenetic silencing. Among these, the TRIM28–EZH2 interaction is central to maintaining repressive chromatin states that promote tumorigenesis. In this study, we modeled the TRIM28–EZH2 complex using protein–protein docking, revealing a stable interface dominated by the RBCC domain of TRIM28 and the PRC2 catalytic domain of EZH2. A cysteine‐focused covalent inhibitor library was screened to identify small molecules capable of targeting reactive cysteines at the interface. Four lead compounds were identified, with compound C87 exhibiting the most favorable binding free energy (Δ G bind = −57.2 kcal/mol) and stable interactions throughout molecular dynamics simulations. These findings highlight the potential of covalent inhibition as a novel strategy to disrupt oncogenic TRIM28–EZH2 complexes and restore tumor suppressor gene expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Bio-Computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
- School of Chemistry and Physics, Westville Campus, University of KwaZulu-Natal, Durban, South Africa.
- Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
ORCID-Profile: Ibrahim Oluwatobi Kehinde, Mahmoud E S Soliman
Zitieren
APA
Kehinde, I. O., Mzozoyana, V., Zamisa, S. J., Faya, M., & Soliman, M. E. S. (2026). Targeting the TRIM28–EZH2 Protein–Protein Interface With Cysteine‐Reactive Covalent Inhibitors: A Computational Blueprint for Cancer Therapy. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202502892
Vancouver
Kehinde IO, Mzozoyana V, Zamisa SJ, Faya M, Soliman MES. Targeting the TRIM28–EZH2 Protein–Protein Interface With Cysteine‐Reactive Covalent Inhibitors: A Computational Blueprint for Cancer Therapy. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202502892
BibTeX
@article{Kehinde2026,
author = {Kehinde, Ibrahim Oluwatobi and Mzozoyana, Vuyisa and Zamisa, Sizwe J and Faya, Mbuso and Soliman, Mahmoud E S},
title = {Targeting the TRIM28–EZH2 Protein–Protein Interface With Cysteine‐Reactive Covalent Inhibitors: A Computational Blueprint for Cancer Therapy},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.202502892}
}
EUVIMED